vilanterol (GW642444H) / GSK - LARVOL DELTA

Single-Inhaler Triple Therapy Is Useful for Achieving Clinical Remission in Patients With Bronchial Asthma by Improving Asthma Control Test Scores (ATS 2025) - "The Japan Asthma Society has proposed clinical remission (CR) as the treatment goal for bronchial asthma. Based on their medical records, bronchial asthma patients who were newly prescribed fluticasone furoate 200 / umeclidinium bromide / vilanterol trifenatate (FF (200) / UMEC / VI) at our hospital by the end of August 2024 were investigated. FF (200) / UMEC / VI can contribute to the achievement of CR in patients with bronchial asthma."

Clinical • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Evaluation of Patient-Reported Outcomes (PRO) and Satisfaction With Once-daily Vilanterol/Fluticasone Furoate (VI/FF) in Uncontrolled Asthma Patients Experiencing Frequent Exacerbations on Conventional Treatment: Sub Group Analysis of a Real World Study (ATS 2025) - "Patients with uncontrolled asthma experiencing frequent exacerbations on conventional therapy showed high adherence to treatment when switched to VI/FF. This adherence was linked to increased patient satisfaction & significant improvement in asthma symptoms, indicating VI/FF a promising option for this group."

Clinical • Patient reported outcomes • Real-world • Real-world evidence • Asthma • Cough • Immunology • Pain • Respiratory Diseases

Economic Evaluation of Single-Inhaler Extrafine Beclometasone Dipropionate/formoterol fumarate/glycopyrronium (Trimbow®) in Adult Patients with Uncontrolled Asthma in Mexico (ISPOR 2025) - "The annual per-patient cost for BDP/FF/G was $3,881.34, compared to Beclometasone/Formoterol ($4,373.36), Budesonide/Formoterol ($6,098.29), Salmeterol/Fluticasone ($14,014.57), and Fluticasone/Vilanterol ($14,096.49). The extrafine SITT with BDP/FF/G is a dominant therapeutic option for adults with uncontrolled asthma in Mexico, delivering superior asthma control, significantly reducing exacerbations, and lowering annual per-patient costs compared to therapies currently used by IMSS."

Clinical • HEOR • Asthma • Immunology • Respiratory Diseases

Inhalation Safety and Tolerability of a Novel Fixed Dose Combination of Glycopyrronium-Vilanterol Powder in Wistar Rats. (PubMed, Toxicol Mech Methods) - "Minimal, non-dose-related microscopic lesions and normal alveolar macrophage responses were observed. The No-Observed-Adverse-Effect Level (NOAEL), based on actual concentration and duration of exposure, was established at 25 + 50 mcg/kg/day, indicating the FDC's safety and suitability for further development in COPD management."

Journal • Preclinical • Chronic Obstructive Pulmonary Disease • Immunology • Ophthalmology • Pulmonary Disease • Respiratory Diseases

U-LABA/ICS Effects on Exercise Performance, Vilanterol (clinicaltrials.gov) - P=N/A | N=30 | Recruiting | Sponsor: Morten Hostrup, PhD | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Sep 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date

Role of Lung Function for Exercise Capacity in Well-trained Individuals (clinicaltrials.gov) - P=N/A | N=60 | Recruiting | Sponsor: Morten Hostrup, PhD | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Sep 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Inflammation • Respiratory Diseases

Efficacy and safety of maintenance regimens for adolescent and adult asthmatics with exercise-induced bronchospasm: Systematic review and network meta-analysis. (PubMed, J Allergy Clin Immunol Pract) - "Low-dose ICS and as-needed ICS-formoterol were equally effective in managing asthmatics with EIB. Adding anti-leukotrienes or LABA to ICS should be considered for more severe cases, with close monitoring to assess treatment response and detect potential tachyphylaxis or AEs."

Journal • Retrospective data • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Green Approach for Simultaneous Determination of Long Acting β-Agonists, their Organic Counterparts and Corticosteroids by HPLC Coupled with PDA Detector. (PubMed, Ann Pharm Fr) - "The proposed method was accurate, precise and robust and results were within the limit as per the ICH (Q2R1) guidelines. Additionally, the proposed method was found to be green and sustainable when analysed by different green analytical tools namely GAPI, AGREE, AGREEprep and BAGI."

Journal

Repurposing FDA-Approved Drugs for Eumycetoma Treatment: Homology Modeling and Computational Screening of CYP51 Inhibitors. (PubMed, Int J Mol Sci) - "Current treatments, including antifungal drugs like itraconazole, often show variable efficacy, with severe cases necessitating surgical intervention or amputation. To this end, a library of 2619 FDA-approved drugs was screened, identifying three promising candidates: montelukast, vilanterol, and lidoflazine. These compounds demonstrated favorable binding affinities, strong interactions with critical residues of the homology model of Madurella mycetomatis CYP51, and stability in molecular dynamics simulations, offering potential for further investigation as effective therapeutic options for eumycetoma."

FDA event • Journal • Infectious Disease • Oncology

A CASE OF IgG4-RELATED DISEASE WITH CONFIRMED RESPONSE TO DUPILUMAB BY SMALL SALIVARY GLAND BIOPSY (PubMed, Arerugi) - "Fluticasone-vilanterol was introduced, but there was little improvement in the cough. In addition, serum IgG4 levels decreased after the initiation of dupilumab treatment, and a decrease in IgG4-positive plasma cells was observed on small salivary gland biopsy. Thus, the treatment of inhaled steroid-resistant bronchial asthma with dupilumab can also improve IgG4-related disease, and we confirmed a decrease in IgG4-positive plasma cells in the small salivary glands."

Biopsy • Journal • Asthma • Cough • Immunology • Inflammation • Oncology • Pulmonary Disease • Respiratory Diseases • Small Intestinal Carcinoma

In Vitro Analysis of Aerodynamic Properties and Co-Deposition of a Fixed-Dose Combination of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate. (PubMed, Pharmaceutics) - "Spatial distribution and abundance of ICS/LABA/LAMA in the same cascade levels were closely comparable, and the aerosol particles were able to reach the small aerosol-sized cascades at the lower levels to some extent."

Journal • Preclinical • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Sub-Optimal Compliance to Long-Term Inhalation Strategies and Poorer Health Care Outcomes Associated with Extended Tattoos in Adolescents with Mild-to-Moderate Bronchial Asthma. (PubMed, Children (Basel)) - "Tattoo extension might be used as a reliable predictor of poor compliance and higher health care costs in adolescents with mild-to-moderate asthma. Patients characterized by poor compliance to a long-term therapeutic strategy and tattooing attitude likely share some aspects of their personality profile."

Compliance • Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Clinical benefits with Fluticasone furoate/Umeclidinium/Vilanterol therapy for COPD: post hoc subgroup analysis of ELLITHE study (ERS 2024) - "In COPD patients of this ELLITHE subanalysis, odSITT improved CAT score independent of specified baseline criteria. Despite overlap in response, individual outcome assessments are necessary to fully comprehend differential benefits of real-world odSITT beyond exacerbations."

Clinical • Retrospective data • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

β2-agonists induce and augment rhinovirus-induction of pro-inflammatory mediators in bronchial epithelial cells. (ERS 2024) - "Methods BEAS-2B BECs were stimulated with vehicle control or 0.1-100nM of short-acting or long-acting β2-agonists (LABAs), ultra-LABAs and short or long-acting muscarinic antagonists; +/- rhinovirus(RV)-A16 infection to mimic use during exacerbations; +/- 10nM fluticasone propionate (furoate with vilanterol)...This may explain the adverse effects associated with β2-agonist use without ICS. In vivo studies need to determine the clinical significance of these findings."

Asthma • Immunology • Infectious Disease • Respiratory Diseases • BDNF • IL6

CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8+ T cells. (PubMed, Gut) - "Vilanterol plus the STING agonist sensitised PDAC to CLDN18.2 BiTEs and augmented efficacy as a potential novel strategy."

Journal • Fibrosis • Gastrointestinal Cancer • Hepatology • Immunology • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CAFs • CD8 • CLDN18 • RHOA • STING • SYK

Comparison of Budesonide/formoterol versus Fluticasone furoate/vilanterol as maintenance and reliever therapy for asthma control: a real-world observational study. (PubMed, BMC Pulm Med) - "In the current study, patients treated with FF/VIL as MART showed improvements in ACT scores, while those treated with BUD/FOR as MART exhibited a reduction in FeNO levels. However, the difference between the two treatment groups did not reach clinical significance. Thus, FF/VIL as MART showed similar effectiveness to BUD/FOR as MART."

Journal • Observational data • Real-world • Real-world evidence • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Comparison of the Genomic Activity of an EP4-Receptor and β2-Adrenoceptor Agonist in BEAS-2B Human Bronchial Epithelial Cells: In Search of Compartmentalized, cAMP-dependent Gene Expression. (PubMed, J Pharmacol Exp Ther) - "Herein, we used mRNA-seq to compare the transcriptomic responses produced by ONO-AE1-329 (an EP4-receptor agonist) and vilanterol (a β2-adrenoceptor agonist) in BEAS-2B human airway epithelial cells...Furthermore, ONO-AE1-329 behaved as a partial agonist that varied across transcripts. If this genomic activity is reproduced in vivo, then EP4-receptor agonists could represent an alternative, and possibly safer, class of bronchodilators."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Effect of fluticasone propionate/formoterol and fluticasone furoate/vilanterol on adolescents with chronic bronchial obstruction. (PubMed, J Allergy Clin Immunol Glob) - "Both ICS/LABA combinations demonstrated significant improvements in FEV1z score. More than one-third of the asthmatic adolescents with prolonged bronchial obstruction achieved a normal prebronchodilator FEV1/FVC ratio."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Clinically Relevant β2-agonists Induce and Augment Rhinovirus-induction of Asthma-relevant Pro-inflammatory Mediators in Human Bronchial Epithelial Cells (ATS 2024) - " BEAS-2B BECs were stimulated with SABAs (fenoterol, salbutamol), LABAs (formoterol, salmeterol), ultra-LABAs (indacaterol, olodaterol, vilanterol), short-acting (ipratropium) or long-acting (tiotropium, aclidinium, umeclidinium) muscarinic antagonists, at concentrations 0. β2-agonists upregulate BEC production of asthma-relevant pro-inflammatory mediators, while muscarinic antagonists do not. β2-agonists also augment RV-induction of disease-relevant mediators. Corticosteroid co-administration abolishes these pro-inflammatory effects."

Clinical • Late-breaking abstract • Asthma • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • BDNF • IL6

Severe Bullous Emphysema Induced by Crack Cocaine Use (ATS 2024) - "The patient was started on Methylprednisolone 40 mg IV every twelve hours, Ceftriaxone 2 g IV daily, and Doxycycline 100 mg every twelve hours...He was prescribed Umeclidinium bromide / Vilanterol as maintenance therapy...BE is frequently asymptomatic and discovered by chance on imaging. Ensuring correct diagnosis and treatment will improve the outcomes in this patient population."

Cardiovascular • Cough • Fatigue • Hematological Disorders • Hypertension • Infectious Disease • Inflammation • Pneumonia • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Septic Shock • Transplantation

Triple Therapy and Clinical Control in B+ COPD Patients: A Pragmatic, Prospective, Randomized Trial. (PubMed, Arch Bronconeumol) - "The ANTES B+ study is the first to: (1) explore the efficacy and safety of triple therapy in a population of B+ COPD patients and (2) use a composite index (CC) as the primary result of a COPD trial."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Efficacy and Safety of Once-Daily Vilanterol/Fluticasone Furoate MDI in Persistent Asthma: Phase 3 OD-INHALE study. (PubMed, J Asthma) - "The low dose VI/FF had similar efficacy to that of low dose FOR/FP and high dose VI/FF had similar efficacy to high dose FOR/FP. No serious adverse events were reported during the study. Once daily VI/FF pMDI was non-inferior to twice daily FOR/FP pMDI in patients with persistent asthma."

Journal • P3 data • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Stability-indicating UPLC assay coupled with mass spectrometry for the analysis of vilanterol degradation products in human urine. (PubMed, Sci Rep) - "Samples collection and experimental protocol was performed according to the guidelines of the Research Ethics Committee of the Faculty of Pharmacy, the British University in Egypt with approval No. CH-2305."

Journal • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Trend of Bronchial Hyperresponsiveness to Methacholine as a Cost Predictor of Mild-to-Moderate Asthma: A Twelve-Month Survey in Teenagers. (PubMed, Children (Basel)) - "the usual spirometric parameters are largely insufficient to reflect the effects of underlying persistent inflammation in milder forms of asthma in teenagers. In terms of clinical governance, the periodic assessment of non-specific BHR is the appropriate procedure from this point of view. Non-specific BHR proves a reliable procedure for predicting and monitoring the economic impact of mild-to-moderate asthma in teenagers over time."

Journal • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Leukotriene Inhibitors Effect on Post-Traumatic Osteoarthritis: A Real-World Evidence Comparative Effectiveness Study (ACR Convergence 2023) - "Additionally, subjects had to be users of leukotriene inhibitors (montelukast, zafirlukast, or zileuton) or an active comparator that consisted of long-acting beta agonists (albuterol, arformoterol, formoterol, indacaterol, olodaterol, salmeterol, terbutaline, or vilanterol) for any duration from the index date up to 6 months after. Users of leukotriene inhibitors undergoing ACL or meniscal surgery may have lower odds of post-traumatic OA compared with users of long-acting beta agonists."

Clinical • HEOR • Real-world • Real-world evidence • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Musculoskeletal Diseases • Orthopedics • Osteoarthritis • Pain • Pulmonary Disease • Respiratory Diseases • Rheumatology